Immunoscintigraphy with biosynthetically-labeled 75Se-antibodies--I. Biodistribution of 75Se-monoclonal antibodies and of free radionuclide.
Biosynthetically-radiolabeled MoAbs provide a tool to test whether structural modifications of the MoAbs influence the results of conventional immunoscintigraphy. When biosynthetically-labeled 75Se-MoAbs from the Mel-14 hybridoma were injected into mice with melanoma xenografts, the high tumor recovery supported the hypothesis of a structural advantage. The increased excretion of 75Se obtained by supplementing the diet of the mice with cold selenium did not reduce the tumor recovery, demonstrating an accumulation of the free radionuclide in normal tissue.
Ryser
J E
JE
Division of Nuclear Medicine, University Hospital of Geneva, Switzerland.
Carrel
S
S
Buchegger
F
F
Donath
A
A
D000284:Administration, Oral; D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D007553:Isotope Labeling / Q000379:methods; D008545:Melanoma / Q000000981:diagnostic imaging / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011877:Radionuclide Imaging; D012643:Selenium / Q000008:administration & dosage; D012644:Selenium Radioisotopes / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D012644:Selenium Radioisotopes; D012643:Selenium